BRIDGEWATER, N.J., Nov. 5, 2019 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that management will present at the
following investor conferences:
- The Credit Suisse 28th Annual Healthcare Conference
in Scottsdale, AZ on Tuesday, November 12, 2019 at 10:20 a.m. MT.
- The Stifel 2019 Healthcare Conference in New York, NY on Tuesday, November 19, 2019 at 4:10 p.m. ET.
Each fireside chat will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcasts will be archived for a period of 90
days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product, ARIKAYCE®
(amikacin liposome inhalation suspension), is the first and only
therapy approved in the United
States for the treatment of refractory Mycobacterium
avium complex (MAC) lung disease as part of a combination
antibacterial drug regimen for adult patients with limited or no
alternative treatment options. MAC lung disease is a chronic,
debilitating condition that can cause severe and permanent lung
damage. Insmed's earlier-stage clinical pipeline includes INS1007,
a novel oral reversible inhibitor of dipeptidyl peptidase 1 with
therapeutic potential in non-cystic fibrosis bronchiectasis and
other inflammatory diseases, and INS1009, an inhaled formulation of
a treprostinil prodrug that may offer a differentiated product
profile for rare pulmonary disorders, including pulmonary arterial
hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-two-november-conferences-300951470.html
SOURCE Insmed Incorporated